EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis

Antti Kokko, Päivi Laiho, Rainer Lehtonen, Sanna Korja, Luis Carvajal-Carmona, Heikki Järvinen, Jukka Pekka Mecklin, Charis Eng, Johanna Schleutker, Ian P M Tomlinson, Pia Vahteristo, Lauri A. Aaltonen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Ephrin receptor B2 (EPHB2) has recently been proposed as a novel tumor suppressor gene in colorectal cancer (CRC). Inactivation of the gene has been shown to correlate with progression of colorectal tumorigenesis, and somatic mutations have been reported in both colorectal and prostate tumors. Methods: Here we have analyzed the EPHB 2 gene for germline alterations in 101 individuals either with 1) CRC and a personal or family history of prostate cancer (PC), or 2) intestinal hyperplastic polyposis (HPP), a condition associated with malignant degeneration such as serrated adenoma and CRC. Results: Four previously unknown missense alterations were observed, which may be associated with the disease phenotype. Two of the changes, 1361V and R568W, were identified in Finnish CRC patients, but not in over 300 Finnish familial CRC or PC patients or more than 200 population-matched healthy controls. The third change, D861N, was observed in a UK HPP patient, but not in additional 40 UK HPP patients or in 200 UK healthy controls. The fourth change R80H, originally identified in a Finnish CRC patient, was also found in 1/106 familial CRC patients and in 9/281 healthy controls and is likely to be a neutral polymorphism. Conclusion: We detected novel germline EPHB2 alterations in patients with colorectal tumors. The results suggest a limited role for these EPHB2 variants in colon tumor predisposition. Further studies including functional analyses are needed to confirm this.

Original languageEnglish (US)
Article number145
JournalBMC Cancer
Volume6
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Ephrin-B2
Eph Family Receptors
Colorectal Neoplasms
Prostatic Neoplasms
Intestinal Polyposis
Gene Silencing
Tumor Suppressor Genes
Adenoma
Prostate
Colon
Carcinogenesis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kokko, A., Laiho, P., Lehtonen, R., Korja, S., Carvajal-Carmona, L., Järvinen, H., ... Aaltonen, L. A. (2006). EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. BMC Cancer, 6, [145]. https://doi.org/10.1186/1471-2407-6-145

EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. / Kokko, Antti; Laiho, Päivi; Lehtonen, Rainer; Korja, Sanna; Carvajal-Carmona, Luis; Järvinen, Heikki; Mecklin, Jukka Pekka; Eng, Charis; Schleutker, Johanna; Tomlinson, Ian P M; Vahteristo, Pia; Aaltonen, Lauri A.

In: BMC Cancer, Vol. 6, 145, 01.06.2006.

Research output: Contribution to journalArticle

Kokko, A, Laiho, P, Lehtonen, R, Korja, S, Carvajal-Carmona, L, Järvinen, H, Mecklin, JP, Eng, C, Schleutker, J, Tomlinson, IPM, Vahteristo, P & Aaltonen, LA 2006, 'EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis', BMC Cancer, vol. 6, 145. https://doi.org/10.1186/1471-2407-6-145
Kokko, Antti ; Laiho, Päivi ; Lehtonen, Rainer ; Korja, Sanna ; Carvajal-Carmona, Luis ; Järvinen, Heikki ; Mecklin, Jukka Pekka ; Eng, Charis ; Schleutker, Johanna ; Tomlinson, Ian P M ; Vahteristo, Pia ; Aaltonen, Lauri A. / EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. In: BMC Cancer. 2006 ; Vol. 6.
@article{0233467131ea4edf9af5278df1e198e7,
title = "EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis",
abstract = "Background: Ephrin receptor B2 (EPHB2) has recently been proposed as a novel tumor suppressor gene in colorectal cancer (CRC). Inactivation of the gene has been shown to correlate with progression of colorectal tumorigenesis, and somatic mutations have been reported in both colorectal and prostate tumors. Methods: Here we have analyzed the EPHB 2 gene for germline alterations in 101 individuals either with 1) CRC and a personal or family history of prostate cancer (PC), or 2) intestinal hyperplastic polyposis (HPP), a condition associated with malignant degeneration such as serrated adenoma and CRC. Results: Four previously unknown missense alterations were observed, which may be associated with the disease phenotype. Two of the changes, 1361V and R568W, were identified in Finnish CRC patients, but not in over 300 Finnish familial CRC or PC patients or more than 200 population-matched healthy controls. The third change, D861N, was observed in a UK HPP patient, but not in additional 40 UK HPP patients or in 200 UK healthy controls. The fourth change R80H, originally identified in a Finnish CRC patient, was also found in 1/106 familial CRC patients and in 9/281 healthy controls and is likely to be a neutral polymorphism. Conclusion: We detected novel germline EPHB2 alterations in patients with colorectal tumors. The results suggest a limited role for these EPHB2 variants in colon tumor predisposition. Further studies including functional analyses are needed to confirm this.",
author = "Antti Kokko and P{\"a}ivi Laiho and Rainer Lehtonen and Sanna Korja and Luis Carvajal-Carmona and Heikki J{\"a}rvinen and Mecklin, {Jukka Pekka} and Charis Eng and Johanna Schleutker and Tomlinson, {Ian P M} and Pia Vahteristo and Aaltonen, {Lauri A.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1186/1471-2407-6-145",
language = "English (US)",
volume = "6",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis

AU - Kokko, Antti

AU - Laiho, Päivi

AU - Lehtonen, Rainer

AU - Korja, Sanna

AU - Carvajal-Carmona, Luis

AU - Järvinen, Heikki

AU - Mecklin, Jukka Pekka

AU - Eng, Charis

AU - Schleutker, Johanna

AU - Tomlinson, Ian P M

AU - Vahteristo, Pia

AU - Aaltonen, Lauri A.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Background: Ephrin receptor B2 (EPHB2) has recently been proposed as a novel tumor suppressor gene in colorectal cancer (CRC). Inactivation of the gene has been shown to correlate with progression of colorectal tumorigenesis, and somatic mutations have been reported in both colorectal and prostate tumors. Methods: Here we have analyzed the EPHB 2 gene for germline alterations in 101 individuals either with 1) CRC and a personal or family history of prostate cancer (PC), or 2) intestinal hyperplastic polyposis (HPP), a condition associated with malignant degeneration such as serrated adenoma and CRC. Results: Four previously unknown missense alterations were observed, which may be associated with the disease phenotype. Two of the changes, 1361V and R568W, were identified in Finnish CRC patients, but not in over 300 Finnish familial CRC or PC patients or more than 200 population-matched healthy controls. The third change, D861N, was observed in a UK HPP patient, but not in additional 40 UK HPP patients or in 200 UK healthy controls. The fourth change R80H, originally identified in a Finnish CRC patient, was also found in 1/106 familial CRC patients and in 9/281 healthy controls and is likely to be a neutral polymorphism. Conclusion: We detected novel germline EPHB2 alterations in patients with colorectal tumors. The results suggest a limited role for these EPHB2 variants in colon tumor predisposition. Further studies including functional analyses are needed to confirm this.

AB - Background: Ephrin receptor B2 (EPHB2) has recently been proposed as a novel tumor suppressor gene in colorectal cancer (CRC). Inactivation of the gene has been shown to correlate with progression of colorectal tumorigenesis, and somatic mutations have been reported in both colorectal and prostate tumors. Methods: Here we have analyzed the EPHB 2 gene for germline alterations in 101 individuals either with 1) CRC and a personal or family history of prostate cancer (PC), or 2) intestinal hyperplastic polyposis (HPP), a condition associated with malignant degeneration such as serrated adenoma and CRC. Results: Four previously unknown missense alterations were observed, which may be associated with the disease phenotype. Two of the changes, 1361V and R568W, were identified in Finnish CRC patients, but not in over 300 Finnish familial CRC or PC patients or more than 200 population-matched healthy controls. The third change, D861N, was observed in a UK HPP patient, but not in additional 40 UK HPP patients or in 200 UK healthy controls. The fourth change R80H, originally identified in a Finnish CRC patient, was also found in 1/106 familial CRC patients and in 9/281 healthy controls and is likely to be a neutral polymorphism. Conclusion: We detected novel germline EPHB2 alterations in patients with colorectal tumors. The results suggest a limited role for these EPHB2 variants in colon tumor predisposition. Further studies including functional analyses are needed to confirm this.

UR - http://www.scopus.com/inward/record.url?scp=33746381505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746381505&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-6-145

DO - 10.1186/1471-2407-6-145

M3 - Article

C2 - 16740153

AN - SCOPUS:33746381505

VL - 6

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 145

ER -